The Central Drugs Standard Control Organization’s Subject Expert Committee has granted Zydus Cadila’s three-dose vaccine emergency use authorization in India. The vaccine can be administered to people aged 12 and above.
‘Phase 3 clinical trials has been the largest trial so far in India for Covid-19 vaccines and the results show that primary efficacy of 66.6% for symptomatic RT-PCR positive cases.’
ZyCoV-D is a first of its kind DNA vaccine that produces the spike protein of the SARS-CoV-2 to elicit an immune response. It is an intradermal vaccine that has to be applied using a ‘needle-free injector’, which, the manufacturer says, will help in reducing side effects.
Earlier, Union Health Minister Mansukh Mandaviya, in a tweet, said: “Double good news for the nation! CDSCO_INDIA_INF approves the 1st DNA-based, needle-free COVID19 vaccine in the world ‘ZyCov-D’. Making children of India COVID-safe, this vaccine can be used for individuals aged 12 and above.
“‘ZyCov-D’ is the 6th approved COVID19 vaccine in India, and the 2nd indigenously developed one”, he said in another tweet.
The interim results from Phase 3 clinical trials, involving over 28,000 volunteers, showed primary efficacy of 66.6 percent for symptomatic RT-PCR positive cases. This has been the largest trial so far in India for Covid-19 vaccines.
Source: IANS
